Tenders Are Invited For Medicinal Products For The Musculo-Skeletal System – Burosumab

Medicinal Products For The Musculo-Skeletal System – Burosumab. The Subject Of The Contract Is The Supply Of The Drug: Burosumab 20 Mg Injection Solution And Burosumab 30 Mg Injection Solution With The Active Substance Burosumab, Known As Crysvita (Hereinafter Only The Product), For Pediatric Patients With X-Linked Form Of Hypophosphatemic Rickets When All The Criteria Listed Below Are Met: 1) With A Documented High Serum Concentration Of Fgf-23 2) With A Genetically Confirmed Mutation In The Phex Gene 3) Persistence Of Low Hypophosphatemia Despite Long-Term Substitution With Maximum Tolerated Doses Of Phosphate Solution And Active Form Of Vitamin D 4) In The Progression Of Bone Deformities Despite Administration Of Maximum Tolerated Doses Of Standard Treatment (Phosphates And Vitamin D).